Retrospective Analysis Of LHRH Analogue Treating Elderly And High Risk Patients Having Urinary Retention With Benign Prostate Hyperplasia

Background and purposePatients of benign prostate hyperplasia have increased dramatically in the setting of continuous development of health care system and the aging of population. With severe chronic medical disease, some elderly and high risk patients with benign prostate hyperplasia develop urinary retention. Due to their limited life expectancy, most of them cannot endure surgical intervention and current solution is either long-term urinary catheter retention or cystostomy, which affects patients’quality of life greatly. To treat elderly and high risk patients having urinary retention with benign prostate hyperplasia, we use Luteinizing Hormone Releasing Hormone(LHRH) analogue and assess its clinical outcome.MethodsClinical data of 15 patients having urinary retention with benign prostate hyperplasia in Sir Run Run Shaw hospital from 1, Jan,2011 to 1, Oct,2015 was retrospectively reviewed using Sir Run Run Shaw hospital’s electronic medical record system. These 15 patients underwent cystostomy and received LHRH analogue regularly. Successful cystostomy catheter removal rate, International Prostate Symptom Score (IPSS), Quality of Life(QOL) score, Maximum flow rate (Qmax), Prostate Volume(PV) variation and Residual Urine Volume (RUV) were observed.ResultsAfter 16-52 weeks’ LHRH analogue treatment, average 29.1±14.0 weeks,12 patients could urinate voluntarily, accounting for 80%. In these 12 patients, IPSS was 31.5±2.8, and QOL was 4.9±0.9 before treatment; After successfully removing the cystostomy catheter, IPSS was 18.9±4.3, QOL was 2.4±0.5 and t test showed that P< O.OOl.One month follow-up of these 12 patients showed that RUV was 22.7±16.1 ml and Qmax was 10.9±1.6ml/s. For all 15 patients receiving LHRH analogue treatment, PV was 62.9±19.7ml before treatment and PV was 43.4±10.2ml 12 weeks after(t test showed that P<0.001)and average reduction was 29±0.1%.ConclusionsThe clinical outcome of LHRH analogue treating elderly and high risk patients having urinary retention with benign prostate hyperplasia is definite.